Astellas Receives Positive CHMP Opinion for XOSPATA® (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
Advertisement
If approved by the European Commission, gilteritinib would represent one of the few advances in Europe for AML over the past 40 years(1)
